Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novavax Inc (NVAX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Novavax IncTrade
DENTSPLY SIRONA IncTrade

Price performance (Past 24H)

Key statistics

Novavax Inc vs DENTSPLY SIRONA Inc — how do they compare? Novavax Inc trades at $7.94 (market cap $1.31B), while DENTSPLY SIRONA Inc trades at $11.38 (market cap $2.31B). The key difference: DENTSPLY SIRONA Inc is the larger of the two by market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

NVAXXRAY
Market Cap
$1.31B$2.31B
Sector
HealthHealth
52-Week High
$11.19$14.68
52-Week Low
$6.22$9.64
Enterprise Value
$889.30M$4.39B
Dividend Yield
5.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novavax Inc

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

DENTSPLY SIRONA Inc

DENTSPLY SIRONA (XRAY) trades at $11.40, down 2.23% amid ongoing revenue declines and negative profitability. The stock shows bearish technical signals with support at $11 and resistance at $12. Recent Q2 2026 earnings beat expectations with $0.52 EPS but revenue fell 4.1% year-over-year to $898 million, reflecting persistent challenges in dental markets. The company maintains a 'Hold' analyst consensus with a $11.50 price target while executing its turnaround strategy.

Investment outlook remains cautious given six consecutive quarters of revenue declines and negative net margins. The company's restructuring efforts and new CFO appointment offer potential for operational improvement, but weak European demand and competitive pressures pose significant headwinds. With debt-to-asset ratio rising to 42.88% in 2025, financial leverage adds risk to the recovery thesis.

Returns comparison

Trailing returns across standard periods

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX

About DENTSPLY SIRONA Inc

Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters

Read more on XRAY